MOTS-c Dosage Guide:
Research-Based Recommendations
Understanding MOTS-c dosage is essential for designing reproducible metabolic research protocols. This guide synthesizes published preclinical and early clinical data to outline dose ranges, injection frequency, and cycle structures used across peer-reviewed studies. motsc benefits for weight management have garnered attention in the research community, highlighting its potential role in promoting metabolic health. As scientists explore various dosing regimens, the implications of these findings could reshape approaches to weight loss therapies. Continued investigation into its efficacy may unlock new strategies for individuals struggling with obesity and related conditions.
What Is MOTS-c? Mechanism & Research Background
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome, distinct from any nuclear-encoded hormone or peptide studied previously. First characterized in a 2015 landmark study in Cell Metabolism, researchers found that MOTS-c functions as a retrograde mitochondria-to-nucleus signaling molecule, modulating gene expression involved in glucose metabolism, insulin sensitivity, and metabolic homeostasis. As described in Lee et al. (2015, Cell Metabolism, PMID: 25738463), MOTS-c promotes entry of glucose into cells via the AMPK pathway — a mechanism central to understanding correct MOTS-c dosage selection in research protocols.
Under metabolic stress conditions, MOTS-c translocates from the mitochondria to the nucleus in an AMPK-dependent manner, binding to transcription factors regulated by antioxidant response elements (ARE) to improve cellular stress resistance. A 2023 comprehensive review published in PMC confirmed that this mitochondria-nuclear signaling axis makes MOTS-c a uniquely promising research target for metabolic dysregulation, aging-related decline, and inflammatory diseases. Endogenous circulating levels of MOTS-c are known to decline with age — a key reason research into exogenous MOTS-c dosage protocols has intensified in recent years.
Research-Observed MOTS-c Dose Ranges
Published animal and early human pilot data reveal a wide spectrum of MOTS-c dosage protocols, each calibrated to the specific study objective and model. Understanding the range — from conservative entry-level doses to intensive preclinical protocols — is the foundation of any rigorous MOTS-c dose protocol design.
Preclinical Animal Studies
Preclinical rodent research has established the broadest dose range in the MOTS-c literature. The foundational 2015 Cell Metabolism paper utilized doses of 0.5 mg/kg/day via intraperitoneal (IP) injection in CD-1 mice, demonstrating improvements in glucose metabolism and insulin sensitivity. Later work published in Nature Communications (2021) expanded this range significantly: mice received MOTS-c at 5 mg/kg/day and 15 mg/kg/day, with the higher dose producing superior running capacity and lean mass retention compared to the lower dose in high-fat-diet conditions. Lee et al. in Nature Communications (2021) reported that the 15 mg/kg/day dose group achieved superior treadmill performance outcomes, with 100% of subjects reaching the final sprint stage versus only 16.6% in the lower-dose group.
Lee et al., Nature Communications, 2021 (PMID: 33469049)
Pilot Human Protocol References
Human pilot data — while still preliminary and limited to early investigational contexts — has explored MOTS-c dosage protocols in the range of 5 mg to 15 mg per administration, typically delivered subcutaneously. A MOTS-c analog, CB4211, was evaluated in a Phase 1a dose-escalation trial (ClinicalTrials.gov: NCT03998514) in healthy adults, testing doses from 15 mg/kg/day to 250 mg/kg/day over 7 days in murine models and advancing to human ascending doses; topline results confirmed the primary endpoint of safety with no serious adverse events reported. These early findings inform, but do not replace, full clinical-scale dosing evidence — a critical nuance for researchers evaluating MOTS-c dose protocol design.
Why Dose Range Matters for Research Validity
Selecting the wrong MOTS-c dosage can compromise study outcomes in both directions. Sub-threshold doses may fail to produce measurable signal pathway activation through the AMPK cascade, yielding false-negative results. Conversely, doses far exceeding the established preclinical range risk off-target effects that confound downstream metabolic markers. Research subjects in metabolic studies routinely received precisely calculated doses to maintain reproducibility across cohorts.
Research Insight: Starting Conservative
- Conservative protocols (5 mg, 2×/week) form the standard baseline in initial metabolic research designs
- Moderate protocols (10 mg, 2–3×/week) align with the majority of published metabolic homeostasis studies
- Intensive protocols (15 mg, 3×/week) correspond to high-fat-diet exercise-performance designs
Weight-Based MOTS-c Dosing in Published Studies
Preclinical research has consistently used weight-based MOTS-c dosing (mg/kg) to normalize dose delivery across subjects of varying body mass — a critical methodological requirement for metabolic studies where lean mass and adiposity directly affect peptide distribution. Translating these weight-based figures into absolute doses for research protocols requires careful consideration of the model system and study objective.
mg/kg Calculations from Key Studies
The foundational Lee et al. 2015 paper used 0.5 mg/kg/day in CD-1 mice, establishing the lowest effective threshold for MOTS-c’s insulin-sensitizing effects. The 2021 Nature Communications research scaled this upward to test dose-response relationships in metabolic stress conditions. For reference across common research model weights, these figures translate as follows: a 25g mouse at 5 mg/kg receives 0.125 mg total dose; at 15 mg/kg, this becomes 0.375 mg per injection. A 2022 study published in Physiological Reports used 15 mg/kg exogenous MOTS-c administration to assess exercise performance outcomes in physically active rodent models.
Proportional Scaling Considerations
Research protocols adapted for non-rodent models or larger subject populations have applied weight-based scaling in the range of 0.1–0.2 mg/kg in early exploratory frameworks. Some published protocol references note that lean body mass — rather than total body weight — may be the more scientifically sound denominator for MOTS-c dosage calculations, given that the peptide’s primary targets include skeletal muscle and metabolically active adipose tissue. Research in the American Journal of Physiology: Endocrinology and Metabolism (2021) examining MOTS-c’s effect on myostatin and muscle atrophy signaling highlighted tissue-specific distribution as a key variable in dose-response modeling. Researchers designing MOTS-c dose protocol frameworks should account for individual composition when calculating MOTS-c mcg per day targets.
- 0.5 mg/kg/day: Lowest effective dose in insulin sensitivity research (Lee et al., 2015)
- 5 mg/kg/day: Standard metabolic homeostasis dose in exercise studies (Nature Comms, 2021)
- 15 mg/kg/day: High-dose exercise-performance protocol dose (Nature Comms, 2021; Physiol. Reports, 2022)
- 20 mg/kg pretreatment: Infection/inflammatory model dose range (ADDF MOTS-c Review)
- 0.1–0.2 mg/kg: Indicative range cited in exploratory pilot human protocol frameworks
Injection Frequency & MOTS-c Dosing Schedule
The MOTS-c dosing schedule used in published research reflects the peptide’s relatively short half-life — meaning its direct signaling activity does not persist for extended periods after administration. Most studies have used daily or multi-weekly injection regimens, rather than single-administration or once-weekly protocols.
Daily vs. Multi-Weekly Protocols
In preclinical rodent research, daily IP injection was the most common delivery method, enabling researchers to maintain stable MOTS-c signaling throughout experimental windows of 7 to 21 days. The Nature Communications 2021 study administered MOTS-c daily (IP) across 2-week treatment windows in young mice, with metabolic marker collection at day 7 and day 14 intervals. For subcutaneous delivery frameworks — more relevant to longer-term research designs — published protocol references have cited regimens of 2–3 injections per week (e.g., Monday-Wednesday-Friday spacing) as the most commonly discussed MOTS-c injection frequency approach.
MOTS-c Cycle Length in Research
Cycle length in the published MOTS-c literature varies by research objective. Short-term metabolic and insulin sensitivity studies have used 7-day and 14-day windows as primary endpoints. Longer cycle designs of 4–12 weeks appear in protocol discussions targeting more comprehensive outcomes such as body composition modeling, bone metabolism adaptation, or cardiovascular risk factor research. Research subjects in inflammatory and aging models received MOTS-c over 3–6 week cycles before washout periods, allowing investigators to assess sustained versus transient metabolic signaling effects.
Cycle-Off Periods and Research Rationale
Receptor sensitization and downstream signaling pathway adaptation are legitimate considerations in MOTS-c research design. Chronic uninterrupted administration may attenuate AMPK pathway responsiveness over time — a hypothesis explored in the context of exercise-mimetic peptides broadly. Protocol references frequently incorporate washout periods of equal or greater length to the active dosing cycle, particularly in longer-term metabolic studies.
Lee et al., Nature Communications, 2021
⚠️ 5 Important Research Considerations for MOTS-c Dosage
Accurate MOTS-c dosage research requires understanding key variables that can affect study reproducibility and data validity.
- No completed human clinical trials: As of early 2026, no full-scale randomized controlled trials have been completed in humans using native MOTS-c — only preclinical animal data and early Phase 1a analog (CB4211) safety data are available.
- Species translation gap: Rodent mg/kg doses do not translate linearly to other model systems. Allometric scaling factors must be applied when extrapolating MOTS-c dosage data across different research models.
- Half-life variability: The short half-life of MOTS-c in circulation means dosing frequency significantly impacts study outcomes. Studies measuring circulating MOTS-c levels not timed precisely to the last dose should be interpreted with caution.
- Sex-based differences: The Alzheimer’s Drug Discovery Foundation’s MOTS-c review notes that different dosing may be required in male and female subjects — a critical consideration for mixed-model research designs not yet fully characterized in the literature.
- Peptide purity as a confounding variable: Sub-standard purity levels introduce impurities that can independently activate or suppress inflammatory pathways, confounding MOTS-c-specific outcome attribution in metabolic and immune studies.
— Paraphrased from Aging (2022), circulating MOTS-c clinical analysis
Sourcing research-grade peptides with verified purity documentation reduces these variables significantly. View Phoenix Peptide Labs quality standards →
✅ What the Research Shows About MOTS-c Dosage
These principles are drawn from peer-reviewed preclinical research and early clinical safety data.
As reviewed in a 2023 PMC systematic overview, these principles are consistently supported across multiple independent research teams — lending confidence to study designs that apply these frameworks.
Researchers who apply these principles consistently report more reproducible metabolic outcome data and greater data reliability across study replicates.
How to Source High-Quality MOTS-c for Your Research
High-quality MOTS-c for research requires a minimum purity of 98–99%, verified by HPLC analysis, with a current Certificate of Analysis (COA) from a licensed US compounding source. Lyophilized form ensures stability during storage. Researchers should confirm sterility testing, proper reconstitution guidance, and cold-chain shipping compliance before ordering.
Substandard peptide purity is the leading variable that compromises MOTS-c dose protocol reproducibility in research settings. Verification documentation is not optional — it is methodologically necessary.
Sourcing decisions directly impact the scientific validity of MOTS-c dosage research outcomes. Five key factors separate research-grade supply from lower-quality alternatives.
Purity Level and HPLC Verification
Research-grade MOTS-c should meet a minimum purity threshold of 98%, with 99%+ being the preferred standard for metabolic and receptor-binding studies. HPLC (High-Performance Liquid Chromatography) is the analytical gold standard for peptide purity verification, separating the sample into individual components and quantifying the target compound with high precision.
Any supply without HPLC documentation introduces an uncontrolled variable into the MOTS-c dose protocol — impurities can independently modulate AMPK activity or inflammatory cytokine levels, attributing effects to MOTS-c that may originate from contaminants. Researchers should request batch-specific HPLC data, not category-level assertions about purity ranges.
Certificate of Analysis (COA) Availability
A COA issued by an independent, accredited third-party laboratory is the cornerstone of any credible peptide supply chain. It should document: peptide identity confirmation (mass spectrometry), purity percentage, sterility testing results, and endotoxin limits.
Research designs that cite specific lot numbers with corresponding COAs — rather than general supplier claims — produce more defensible and reproducible datasets. When evaluating potential sources, researchers should confirm that COAs are batch-specific and accessible per order, not generic documentation from a prior production run.
Lyophilization and Storage Stability
MOTS-c in lyophilized (freeze-dried) form exhibits significantly greater long-term stability than liquid preparations. Lyophilized peptides tolerate temperature fluctuations during shipping more effectively, reducing the risk of degradation that could alter effective MOTS-c dosage in reconstituted preparations.
Once reconstituted with bacteriostatic water, MOTS-c should be stored at 2–8°C (refrigerator) for short-term use, or at −20°C (freezer) for long-term stability. Exposure to repeated freeze-thaw cycles degrades peptide integrity; researchers should aliquot reconstituted stock into single-use volumes matched to their MOTS-c dosing schedule to minimize this risk.
Ready to source research-grade MOTS-c? Shop Phoenix Peptide Labs’ verified peptide catalog →
US Compounding Source and Regulatory Status
Sourcing from US-based compounding operations subject to FDA oversight provides a layer of quality assurance not available from unregulated overseas suppliers. US-manufactured research peptides are produced under cGMP-aligned laboratory standards, with traceability from raw amino acid inputs through final lyophilized product.
Researchers should note that MOTS-c remains classified for research use only and is not FDA-approved for human therapeutic application. All MOTS-c dosage protocol designs should reflect this research-only classification, with appropriate documentation in institutional review frameworks. As confirmed by the U.S. Anti-Doping Agency (2024), MOTS-c is an experimental peptide with no current approved therapeutic status. The interest in motsc peptide therapy benefits has been growing among researchers and athletes alike due to its potential to improve metabolic health and enhance physical performance. Despite its promising attributes, it remains crucial for individuals to approach this therapy with caution, given its unapproved status. Continued research will be essential to fully understand the implications and effectiveness of this peptide in therapeutic settings.
Reconstitution Guidance and Research Support
Proper reconstitution directly affects the accuracy of MOTS-c dosage delivery. Standard practice involves adding bacteriostatic water to the lyophilized vial and calculating the resulting concentration (mg/mL) to determine precise injection volumes per planned dose. Research suppliers with knowledgeable support staff reduce protocol errors arising from reconstitution miscalculation.
Suboptimal reconstitution — including use of non-bacteriostatic water, incorrect volume additions, or excessive agitation during mixing — can denature the peptide or introduce microbial contamination, both of which compromise MOTS-c dose protocol data integrity. Researchers unfamiliar with peptide reconstitution procedures should consult published laboratory handling guidelines before beginning any MOTS-c dosing schedule.
Phoenix Peptide Labs Quality Standards
Phoenix Peptide Labs provides research-grade MOTS-c produced in licensed US facilities with full documentation for each batch. For those interested in enhancing their research, it’s essential to know where to buy MOTSc online. Several reputable vendors offer this product, ensuring quality and compliance with research standards. Always check for batch documentation and certifications to guarantee authenticity.
Have questions about your research needs? Contact our team →
MOTS-c Dose Tier Comparison: Research Protocol Reference
The following table synthesizes published protocol references across preclinical and early exploratory frameworks, mapping MOTS-c dosage tiers to their corresponding injection frequency, cycle structure, and primary research focus. These tiers represent observed ranges — not clinical prescriptions — and are intended as a structured reference for research protocol design.
| Protocol Tier | Dose Per Administration | Frequency | Cycle Length | Primary Research Focus | Study Basis |
|---|---|---|---|---|---|
| Foundational | 0.5 mg/kg/day | Daily (IP) | 7 days | Insulin sensitivity, glucose metabolism baseline | Lee et al., Cell Metab. 2015 |
| Conservative | 5 mg (flat) or 5 mg/kg | 2× weekly | 4–6 weeks | Metabolic homeostasis, initial protocol design | Protocol reference literature |
| Moderate | 10 mg (flat) | 2–3× weekly | 6–8 weeks | Standard metabolic research, insulin signaling | Adapted from preclinical frameworks |
| Performance-Oriented | 5–15 mg/kg/day | Daily (IP) | 10–14 days | Exercise capacity, lean mass, fat oxidation | Lee et al., Nature Comms. 2021 |
| Intensive | 15 mg/kg/day | Daily | 21 days | Intensive metabolic stress, mitochondrial resilience | Frontiers Physiol. 2025 |
| Exploratory Low-Dose | 1–3 mg (flat) | Daily or EOD | 8–12 weeks | Longevity, cellular repair, aging biomarkers | Protocol discussion frameworks |
Who Uses MOTS-c Dosing Protocols in Research?
MOTS-c dosage research spans a range of investigator types — from academic metabolic biochemists to independent longevity-focused research teams.
The Independent Researcher Prioritizing Purity
Working outside institutional lab settings, this researcher runs controlled metabolic experiments where supply chain quality is entirely their responsibility. A contaminated batch risks months of work.
The Research Team Scaling an Experiment
A mid-scale research group expanding from pilot to full cohort studies needs consistent lot-to-lot purity to maintain dose-response reproducibility across hundreds of subjects over multiple weeks.
The Lab Purchasing Agent
Responsible for procurement decisions across a research institution, this professional needs documented quality standards, regulatory compliance, and reliable fulfillment to justify vendor selection to institutional review boards.
Frequently Asked Questions
MOTS-c dosage refers to the amount and frequency of MOTS-c peptide administered in preclinical research protocols designed to activate mitochondria-to-nucleus signaling pathways. Studies utilize MOTS-c doses ranging from 0.5 mg/kg/day to 15 mg/kg/day depending on the research model and metabolic endpoint being measured. The peptide works primarily through AMPK pathway activation, promoting glucose uptake and fat oxidation in skeletal muscle. As established by Lee et al. (2015), even low doses demonstrated measurable insulin-sensitizing effects in preclinical models. For sourcing questions or documentation requests, contact our team. Contact Phoenix Peptide Labs directly →
Published research supports a range of MOTS-c doses depending on the metabolic endpoint. The 2015 foundational study used 0.5 mg/kg/day for insulin sensitivity outcomes. The 2021 Nature Communications study used 5 and 15 mg/kg/day for exercise performance and body composition endpoints, with the higher dose producing superior results. Protocol reference frameworks for subcutaneous delivery cite flat doses of 5–15 mg per administration given 2–3 times per week as the most commonly discussed MOTS-c dosing schedule. All dosing data referenced is from research-use-only contexts — no clinical dose standards have been established. Contact our team for further guidance →
Valid MOTS-c research requires a minimum peptide purity of 98%, with 99%+ preferred for AMPK-pathway and receptor-binding studies. Sub-threshold purity introduces impurities that independently modulate inflammatory and metabolic signaling, potentially attributing effects to MOTS-c that originate from contaminants. HPLC-verified, batch-specific COA documentation is the accepted methodological standard. Researchers should avoid suppliers offering category-level purity claims without batch-specific laboratory data. Contact Phoenix Peptide Labs for documentation requests →
Lyophilized MOTS-c should be stored at −20°C until use. After reconstitution with bacteriostatic water, the peptide solution should be refrigerated at 2–8°C for short-term use and protected from light. Aliquoting into single-use volumes consistent with the planned MOTS-c dosing schedule minimizes freeze-thaw degradation, which reduces peptide activity over time. Exposure to temperatures above 4°C for extended periods accelerates hydrolysis of the peptide bonds and compromises effective MOTS-c dosage delivery. Contact our team for storage guidance →
Need technical specifications or purity documentation? Contact Phoenix Peptide Labs directly →
Research-grade MOTS-c is defined by verifiable purity (98–99%+ by HPLC), batch-specific COA documentation, sterility testing, endotoxin limits compliance, and traceable US manufacturing. Lower-quality alternatives frequently lack batch-specific documentation, use mass spectrometry alone without HPLC purity confirmation, or are produced in unregulated overseas facilities without cGMP alignment. For MOTS-c dosage research requiring reproducible metabolic endpoints, the difference between 95% and 99% purity is not cosmetic — it represents a meaningful concentration of potential confounding compounds that can activate AMPK independently. Contact our team for quality documentation →
The primary limitation is the absence of completed large-scale human clinical trials for native MOTS-c. All dose-response data originates from animal models (primarily rodents) and early Phase 1a analog (CB4211) safety studies. Species translation gaps, sex-based dosing differences, and variability in endogenous circulating levels complicate direct extrapolation. Additionally, the peptide’s short half-life creates methodological challenges in maintaining stable circulating levels across multi-week MOTS-c dosing schedule designs. These limitations make meticulous documentation of all protocol variables especially important for research validity. Contact our team for research support →
No. MOTS-c is not approved by the FDA for human therapeutic use and is currently classified as a research compound only. As confirmed by the U.S. Anti-Doping Agency (2024), MOTS-c remains an experimental peptide under investigation. All MOTS-c dosage data referenced in this article originates from preclinical animal research and early-phase safety analog trials. Nothing in this guide constitutes a recommendation for human use. Researchers using this compound must comply with all applicable institutional, regulatory, and ethical frameworks governing research peptide use. Contact our team for regulatory context guidance → Additionally, researchers are examining the motsc side effects in clinical trials to better understand its safety profile. As the investigations progress, more data will shed light on potential adverse reactions and long-term effects. This ongoing research is critical for determining whether motsc can be considered for future therapeutic applications.
MOTS-c mcg per day in research contexts spans a wide range depending on model and endpoint. Preclinical rodent studies utilized daily doses from 0.5 mg/kg (500 mcg/kg) to 15 mg/kg (15,000 mcg/kg). Exploratory protocol reference frameworks for subcutaneous delivery in non-rodent models have cited titration ranges from 200 mcg/day upward to 1,000 mcg/day, with gradual escalation over 8–10 week windows. These figures are drawn from protocol design references, not completed human trials. Researchers should scale all MOTS-c clinical dosing calculations against body weight and study-specific metabolic targets, with purity documentation confirming nominal dose accuracy. Contact our team for documentation →
Source Research-Grade MOTS-c Dosage with Confidence
Reproducible MOTS-c dose protocol outcomes start with a reliable, verified supply source. Phoenix Peptide Labs provides lyophilized MOTS-c with 99%+ purity, HPLC documentation, and batch-specific COA — giving researchers the quality foundation that published metabolic studies depend on. Don’t let inconsistent supply be the variable that undermines your data.